[Pathogenesis and alpha-2 interferon treatment of chronic hepatitis B].
Pirotte
J
J
Service d'Hépato-Gastroentérologie, Université de Liège.
D000998:Antiviral Agents / Q000627:therapeutic use*; D002353:Carrier State; D006508:Hepatitis Antibodies / Q000276:immunology; D006509:Hepatitis B / Q000276:immunology / Q000628:therapy*; D006526:Hepatitis C / Q000150:complications; D003699:Hepatitis D / Q000150:complications; D006521:Hepatitis, Chronic / Q000276:immunology / Q000628:therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D006508:Hepatitis Antibodies; D016898:Interferon-alpha